T. Rowe Price Investment Management’s Avalyn Pharma AVLN Stock Holding History

T. Rowe Price Investment Management’s Portfolio AVLN Stock Details AVLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$52.8M	Buy	+1,602,745	New	+$46.3M	0.03%	388

Other funds holding AVLN

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

CCM

Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PBPIA

Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

T. Rowe Price Investment Management's AVLN Position: Q2 2026 in Review

T. Rowe Price Investment Management opened a new position in Avalyn Pharma (AVLN) in Q2 2026: 1,602,745 shares worth $52.8M. The stake represents 0.03% of the portfolio and ranks #388 among its holdings.

81 funds tracked by Wall St. Rank hold AVLN as of Q2 2026.

T. Rowe Price Investment Management held 1,602,745 shares of Avalyn Pharma worth $52.8M as of Q2 2026.
Avalyn Pharma was a new T. Rowe Price Investment Management position in Q2 2026.
Avalyn Pharma made up 0.03% of T. Rowe Price Investment Management's portfolio in Q2 2026, its #388 holding.
81 funds tracked by Wall St. Rank held Avalyn Pharma as of Q2 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.